AstraZeneca Secures Dual Rare Disease and Bladder Cancer Approvals Across US, Europe
Regulators in the U.S. and European Union handed AstraZeneca Plc (NYSE:AZN) major regulatory wins across rare neuromuscular disease and oncology . The agencies cleared Klygefa for generalized myasthenia gravis and approved the Imfinzi combination regimen for muscle-invasive bladder cancer. FDA And EU Clear Klygefa For Generalized Myasthenia Gravis Monday, the U.S. Food and Drug Administration and…
We haven't written up this one. Benzinga has the full story — the link below goes straight to it.